Shape Graph Mapping of Brain Dynamics Without Dimensionality Loss
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current neuroimaging methods, particularly functional magnetic resonance imaging (fMRI), struggle with clinical translation due to low signal-to-noise ratios and methodological issues, leading to group-averaged tendencies rather than individual-level insights, and face computational inefficiencies in scaling up to larger datasets.
Innovation Solution
The use of a methodological framework that constructs shape graphs from neuroimaging data by leveraging topological data analysis (TDA) techniques, specifically Mapper, with improvements such as intrinsic binning and reciprocal k-nearest neighbors (kNN) graphs, to capture high-dimensional geometry and reduce computational costs, while avoiding dimensionality reduction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional neuroimaging analyses (GLM or functional connectivity) are used, then group-averaged tendencies can be obtained, but individual-level insights are lost due to low signal-to-noise ratio
Solution Approach 1:
The patent segments the high-dimensional neuroimaging data into manageable components through shape graph construction, where nodes represent brain states and edges represent transitions. This segmentation allows individual-level patterns to be extracted without being overwhelmed by noise, enabling both precise measurement and preservation of individual characteristics.
Solution Approach 2:
The patent transforms the data from traditional dimensional spaces into a shape graph dimensionality where topological features (nodes, edges, connectivity patterns) become the analytical units. This dimensional transformation allows individual-level insights to be captured through graph-theoretical metrics while improving signal-to-noise ratio through topological aggregation.
2Quantity of substance
If computational methods are scaled up to larger datasets, then more comprehensive brain dynamics can be mapped, but computational efficiency decreases
Solution Approach 1:
The patent extracts essential topological features (shape graph structure) from the full neuroimaging dataset, separating the critical information needed for analysis from the redundant data. This extraction allows comprehensive brain dynamics to be mapped using only the essential structural features, maintaining computational efficiency even as dataset size increases.
Solution Approach 2:
The patent changes the analytical parameters from traditional voxel-wise or region-wise statistics to shape graph topological parameters (node degrees, betweenness centrality, community structure). This parameter transformation enables scaling to larger datasets because graph-theoretical metrics aggregate information across the entire brain, reducing computational complexity while preserving comprehensive dynamics.
3Productivity
If dimensionality reduction is applied to neuroimaging data, then computational costs are reduced, but high-dimensional geometry information is lost
Solution Approach 1:
Instead of reducing dimensions through projection, the patent transitions to a graph-theoretical dimensionality where the high-dimensional geometry is preserved as topological structure. The shape graph maintains the intrinsic geometry of brain state space by representing distances and connections directly, avoiding information loss while improving computational tractability through graph algorithms.
Data Source
AI summary
Systems and methods for scalable mapping of brain dynamics are capable of mapping brain dynamics in a computationally efficient way. Shape graphs can be produced which can operate as interactive network representations of dynamic brain activity data. In methods for automatically interpreting the structure of the shape graphs, the mapped brain dynamics can be used to indicate which type of treatment protocol is likely to be most effective for the particular individual. The treatment can include transcranial magnetic stimulation, pharmaceutical treatment, and/or any other mental condition treatment as appropriate to the requirements of specific applications.